Last reviewed 2026-05-20 · How we verify

Tripleitriumab

Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2 active Small molecule ✓ Verified May 2026

Tripleitriumab is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently in Phase 2 development. Also known as: JS001.

Tripleitriumab is an antibody that acts as a programmed cell death protein 1 antagonist. It is being studied in combination with Bevacizumab for the treatment of refractory metastatic colorectal cancer with microsatellite stability (MSS) or proficient mismatch repair (pMMR).

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Tripleitriumab
Also known as	JS001
Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tripleitriumab CI brief — competitive landscape report
Tripleitriumab updates RSS · CI watch RSS
Second Affiliated Hospital, School of Medicine, Zhejiang University portfolio CI

Frequently asked questions about Tripleitriumab

What is Tripleitriumab?

Tripleitriumab is a Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who makes Tripleitriumab?

Tripleitriumab is developed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).

Is Tripleitriumab also known as anything else?

Tripleitriumab is also known as JS001.

What development phase is Tripleitriumab in?

Tripleitriumab is in Phase 2.

Manufacturer: Second Affiliated Hospital, School of Medicine, Zhejiang University — full pipeline
Therapeutic area: All drugs in Other
Also known as: JS001

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing